# OnCo record paper-trabectedin-vs-dacarbazine-demetri-jco-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-trabectedin-vs-dacarbazine-demetri-jco-2016" ;
  schema:name "Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure"@en ;
  schema:description "Trabectedin reduced the risk of progression by 45 percent compared with dacarbazine in previously treated liposarcoma and leiomyosarcoma, leading to its approval in the United States, though survival was not improved."@en ;
  schema:url <https://onco.cc/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2015.62.4734>, <https://pubmed.ncbi.nlm.nih.gov/26371143/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2015.62.4734> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Demetri GD, von Mehren M, Jones RL, et al." ;
  onco:cancers <https://onco.cc/cancers/liposarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/> ;
  onco:drugs <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/trabectedin/> ;
  onco:journals <https://onco.cc/journals/jco/> .